Use of agonists of formyl peptide receptor 2 for treating dermatological diseases

Abstract

The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).

What is claimed is: 
     
         1 . A method of treating dermal inflammation or a dermal disease in a subject in need of such treatment, the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a formyl peptide receptor 2 (FPR2) agonist of Formula I: 
       
         
           
           
               
               
           
         
         wherein:
 R 1  is sec-butyl, C 6-10  aryl, —CH 2 — (C 6-10 )aryl, —CH 2 -heterocycle, C 4-8  cycloalkyl or C 3-8  cycloalkenyl or heterocycle; 
 R 2  is halogen or methyl; 
 R 3  is halogen; 
 R 4  is H, methyl or halogen; 
 R 5  is OR 6  or NH 2 ; and 
 R 6  is H or C 2-4  alkyl; 
 
         or a pharmaceutically acceptable salt thereof; 
         or wherein the FPR2 agonist is a compound selected from the group consisting of: 
       
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         and pharmaceutically acceptable salts thereof; 
         and wherein the dermal inflammation or dermal disease is selected from the group consisting of dermal wound healing, hypertrophic scars, keloids, burns, rosacea, atopic dermatitis, acne, psoriasis, seborrheic dermatitis, actinic keratoses, basal cell carcinoma, squamous cell carcinoma, melanoma, viral warts, photoaging, photodamage, melasma, post-inflammatory hyperpigmentation, disorders of pigmentation and alopecia, scarring and non-scarring forms; 
         and wherein the administration is by local delivery. 
       
     
     
         2 . The method of  claim 1 , wherein the compound of Formula I is: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         3 . The method of  claim 1 , wherein the compound is 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         4 . The method of  claim 1 , wherein the local delivery is topical dermal delivery. 
     
     
         5 . The method of  claim 2 , wherein the local delivery is topical dermal delivery. 
     
     
         6 . The method of  claim 3 , wherein the local delivery is topical dermal delivery. 
     
     
         7 . The method of  claim 4 , wherein the pharmaceutical composition is in a form selected from the group consisting of a cream, a lotion, a gel, a solution, a spray, a foam, a suspension and an emulsion. 
     
     
         8 . The method of  claim 5 , wherein the pharmaceutical composition is in a form selected from the group consisting of a cream, a lotion, a gel, a solution, a spray, a foam, a suspension and an emulsion. 
     
     
         9 . The method of  claim 6 , wherein the pharmaceutical composition is in a form selected from the group consisting of a cream, a lotion, a gel, a solution, a spray, a foam, a suspension and an emulsion.